Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --

Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease

New patent covers a treatment method for a broad spectrum of alcohol-related disorders, including additional conditions associated with alcohol use New patent covers a treatment method for a broad spectrum of alcohol-related disorders, including additional conditions associated with alcohol use

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication in Genome Research demonstrating that optical genome Mapping (OGM) can be an accurate, cost-effective method for detecting and sizing large repeat expansions, which are a class of structural variation (SV) linked to as many as 40 genetic disorders. Led by Alexander Hoischen and researchers at Radboud University Medical Center in the Netherlands, the study provides one of the most comprehensive evaluations to date of OGM as a single workflow for characterizing large repeat expansions.

Dublin, April 11, 2025 (GLOBE NEWSWIRE) -- The "Genetic Screening Testing for Preventive Health Market - A Global and Regional Analysis: Focus on Test Type, Technology, Application, End User and Country-Level Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The market for genetic screening testing in preventive health has been experiencing rapid growth, driven by driving factors such as technological advancements, increased consumer interest in personalized medicine, and the rise of preventive healthcare strategies. Several key factors influence the expansion of the genetic screening testing for preventive health market. Improvements in genetic testing technologies, such as next-generation sequencing (NGS), have made these tests more accessible, cost-effective, and accurate. Growing consumer awareness of the benefits of early detection, rising healthcare costs, and an increasing focus on prevention have further fuelled the demand. Moreover, the increasing availability of direct-to-consumer genetic tests has allowed individuals to manage their health. Stakeholders in this market include genetic testing companies, healthcare providers, hospitals, diagnostic laboratories, and wellness-focused organizations. As more people seek personalized, data-driven approaches to healthcare, the demand for genetic screenings as a preventive tool is expected to increase. Moreover, the growing availability of direct-to-consumer genetic testing kits has empowered individuals to take charge of their health and gain insights into their genetic predispositions without necessarily needing a healthcare provider. This trend has significantly expanded the genetic screening market, allowing consumers to access preventive health information more easily. The genetic screening testing for preventive health market is set to witness substantial growth. With continued technological advancements and growing public interest in health optimization and disease prevention, the market offers significant opportunities for healthcare, biotechnology, and wellness stakeholders to meet the rising demand for personalized, proactive health solutions. The development of next-generation sequencing (NGS) technologies and improvements in bioinformatics have made genetic testing more accurate, efficient, and affordable. These innovations allow for comprehensive genetic analysis, enhancing the ability to detect predispositions to various diseases at earlier stages. The continuous evolution of these technologies further drives the demand for genetic screening services in preventive healthcare. Furthermore, there is a growing recognition of the importance of preventive healthcare, with more individuals understanding the benefits of early disease detection and management. Public health campaigns, medical professionals, and organizations have been emphasizing the value of genetic screening to detect health risks before symptoms appear, further driving market demand.

Groundbreaking Yeast Experiment from Dr. Nislow's lab on Last Night's SpaceX Fram2 Mission Advances Space-Based Biotechnology Groundbreaking Yeast Experiment from Dr. Nislow's lab on Last Night's SpaceX Fram2 Mission Advances Space-Based Biotechnology

Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels

FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients